Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.49 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.42 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.42 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | PRKCA | P17252 | 1/20 | 0.42 |
| ▸ | GRK2 | P25098 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11619922 | 0.89 | PTPN1 (0.57) | SMN1; SMN2RAB9APTPN1HCAR2MEN1 | |
| SCHEMBL212382 | 0.85 | RAB9A (0.68) | SMN1; SMN2RAB9APTPN1HCAR2MEN1 | |
| SCHEMBL23930594 | 0.84 | RAB9A (0.50) | SMN1; SMN2RAB9AUSP30MEN1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL8880218 | 0.84 | RAB9A (0.66) | SMN1; SMN2RAB9APTPN1HCAR2MEN1 | |
| SCHEMBL13209809 | 0.83 | PTPN1 (0.47) | SMN1; SMN2RAB9APTPN1HCAR2MEN1 | |
| SCHEMBL15919682 | 0.82 | PTPN1 (0.56) | SMN1; SMN2RAB9APTPN1HCAR2MEN1 | |
| SCHEMBL370074 | 0.81 | CYP2E1 (0.55) | SMN1; SMN2RAB9APTPN1USP30MEN1 | |
| SCHEMBL30516614 | 0.81 | CYP2E1 (0.55) | SMN1; SMN2RAB9APTPN1USP30MEN1 | |
| SCHEMBL3990124 | 0.81 | CHUK (0.47) | SMN1; SMN2RAB9AUSP30IP6K1IP6K3 | |
| SCHEMBL15904105 | 0.81 | SMN1; SMN2 (0.50) | SMN1; SMN2RAB9APTPN1HCAR2USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645771-B2 | CCR5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORP. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20060229336-A1 | Ccr5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORPORATION | 2006-10-12 | — | — | US | disclosed |
| EP-1569646-A2 | PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004054974-A2 | PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229336-A1 | Ccr5 antagonists as therapeutic agents | CCR5, CCR1, CXCR3 | SMN1; SMN2 4065/4885RAB9A 2633/4885PTPN1 3371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.